ARCHIVES

ODAC Nixes Sanofi’s VTE Drug in 14-1 Vote, Setting High Bar For Adjunctive Therapies

This article is from The Cancer Letter archive.

Vol. 38 No. 25 | June 22, 2012

Download PDF Visit The Full Archive

Related Articles

CDC Contribution To National Dialogue Raises Questions About Ties With ACS.

September 22, 2000

DCPC Advisors Okay New Grant Programs To Improve Participation Of Women, Minorities In Clinical Trials

May 26, 1995

NCI Program Announcements

May 5, 2000

Genentech: ODAC Lacks Expertise, Impartiality; FDA: Company’s Proposal Unscientific

August 12, 2011

Clinical Trials Approved By NCI

March 26, 2004

Nucynta ER Approved For Managing Chronic Pain In Adults

September 30, 2011